Bifurkasyon Lezyonlarında Eriyebilen Stentler, İlaç Kaplı Balonlar, Özelleştirilmiş Stentler ve Robotik Stentleme
Özet
Perkütan koroner girişimlerin %15-20'sinde karşılaşılan koroner bifurkasyon lezyonları, anatomik yapılarındaki farklılıklar nedeniyle düşük işlem başarısı ile yüksek tromboz ve restenoz riski taşımaktadır. Geç komplikasyonları azaltmak amacıyla bir yıl içinde tamamen kaybolacak şekilde tasarlanan eriyebilen stentler (ES), kalın destek yapıları, kırılganlıkları ve özellikle akut koroner sendromlarda gözlenen yüksek tromboz ile yeniden girişim oranları nedeniyle halen sınırlı bir klinik kullanıma sahiptir. İlaç kaplı balonlar (İKB), damarda kalıcı metal bir iskelet bırakmadan anti-proliferatif ilaç salınımı sağlayarak, özellikle küçük damar hastalıklarında, yüksek kanama riskinde ve stent içi restenoz vakalarında güvenli ve etkili bir alternatif sunmaktadır. Özelleştirilmiş bifurkasyon stentleri (DBS), çift stent stratejisinin getirdiği metal yükü ve yapısal bozulma gibi mekanik zorlukları aşmak için ana dal, yan dal veya proksimal odaklı (Petal, Tryton, Axxess Plus vb.) özel tasarımlar içermekte ve konvansiyonel tekniklerle benzer bir yıllık klinik sonuçlar göstermektedir. Hekimlerin radyasyon maruziyetini azaltan robotik perkütan koroner girişimler (R-PCI) ise basit ve kompleks lezyonlarda güvenli bulunmuş olup, karmaşık bifurkasyon lezyonlarındaki kullanımı çoklu cihaz kontrolü zorlukları nedeniyle şimdilik olgu sunumları düzeyindedir.
Coronary bifurcation lesions, encountered in 15-20% of percutaneous coronary interventions, carry lower procedural success alongside higher risks of thrombosis and restenosis due to anatomical challenges. Although bioresorbable scaffolds (BRS) are designed to dissolve completely within a year to prevent late complications, their clinical use remains limited because of thick struts, fragility, and high rates of thrombosis and re-intervention, particularly in acute coronary syndromes. Drug-coated balloons (DCB) provide an appealing "leaving nothing behind" alternative by delivering anti-proliferative drugs rapidly into the vessel wall without a permanent metallic cage, demonstrating safety and efficacy in small vessel disease, high bleeding risks, and in-stent restenosis. Dedicated bifurcation stents (DBS) target main, side, or proximal branches (e.g., Petal, Tryton, Axxess Plus) to overcome mechanical limitations of two-stent strategies, such as heavy metal load and strut distortion, yielding comparable one-year clinical outcomes to conventional techniques. Robotic percutaneous coronary intervention (R-PCI) represents a new frontier that reduces radiation exposure for operators; while proven safe and feasible in simple and complex lesions, its application in complex bifurcations remains at the case-report level due to the challenges of managing multiple guidewires simultaneously.
Referanslar
Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? JACC Cardiovasc Interv 2008; 1:218. doi: 10.1016/j.jcin.2007.12.008
Donald Cutlip, J Dawn Abbott ( 2022). Bioresorbable scaffold coronary artery stents. Stephan Windecker, Nisha Parikh (Ed.), Uptodate. Retrieved May, 2022. From https://www.uptodate.com/contents/bioresorbable- scaffold-coronary-artery stents?search=Bioresorbable%20scaffold%20coronary%20artery%20stents
Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med 2015; 373:1905.doi: 10.1056/NEJMoa1509038
Chau KH, Kennedy KF, Messenger JC, et al. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project. JAMA Cardiol 2019; 4:564.doi: 10.1001/jamacardio.2019.0388.
Byrne RA, Stefanini GG, Capodanno D, et al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. EurHeart J 2018; 39:1591. doi: 10.1093/eurheartj/ehx488
Sorrentino S, Giustino G, Mehran R, et al. Everolimus Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. J Am Coll Cardiol 2017; 69:3055. doi: 10.1016/j.jacc.2017.04.011
Byrne RA, Alfonso F, Schneider S, et al. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients under going coronary stenting for myocardial infarction: theIntracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. EurHeart J 2019; 40:167. doi:10.1093/eurheartj/ehy710
Stone GW, Ellis SG, Gori T, et al. Blinded out comes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet 2018; 392:1530.doi: 10.1016/S0140-6736(18)32283-9
Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive networkmeta-analysis. J AmColl Cardiol 2015;65:2496–507. doi:10.1016/j.jacc.2015.04.017
Colombo A, Bramucci E, Sacca S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations:Application of the Crushing Technique Using Sirolimus-ElutingStents) study. Circulation 2009;119:71–8.doi: 10.1161/CIRCULATIONAHA.108.808402
Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006;114:1955–61. doi: 10.1161/CIRCULATIONAHA.106.664920
Zimarino M, Corazzini A, Ricci F, et al. Latethrombosisafterdoubleversussingledrug-elutingstent in thetreatment of coronarybifurcations: a meta-analysis of randomizedandobservationalstudies. J AmCollCardiolIntv 2013;6:687–95.doi: 10.1016/j.jcin.2013.03.012
Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 2010;121:1235–43. doi: 10.1161/CIRCULATIONAHA.109.888297
Lassen JF, Holm NR, Stankovic G, et al. Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings.EuroIntervention 2014;10:545–60.doi: 10.4244/EIJV10I5A97
Kawamoto H, Ruparelia N, Tanaka A, et al. Bioresorbable Scaffolds for the Management of Coronary Bifurcation Lesions. JACC Cardiovasc Interv 2016 May 23;9(10):989-1000. doi: 10.1016/j.jcin.2016.02.038. doi: 10.1016/j.jcin.2016.02.038
Kawamoto H, Latib A, Ruparelia N, et al. Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: overall outcomes and comparison between provisional and planned double stenting strategy. Catheter Cardiovasc Interv 2015;86:644–52. doi: 10.1002/ccd.26045
Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST segment elevation myocardial infarction: BVS STEMI first study. EurHeart J 2014;35:777–86. doi: 10.1093/eurheartj/eht546
Dudek D, Rzeszutko L, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol Arch Med Wewn 2014;124:669–77. doi: 10.20452/pamw.2550
Gori T, Schulz E, Hink U, et al. Clinical,angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes. J Am Coll Cardiol Intv 2015;8:770–7. doi: 10.1016/j.jcin.2014.12.244
Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014;9:103641. doi: 10.4244/EIJV9I9A176
Ielasi A, Cortese B, Varricchio A, et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre “Registro ABSORB Italiano” (RAI registry). EuroIntervention 2015;11:157–62.
Elabbassi W, Chowdhury MA, Hatala R. Use of Bioresorbable Vascular Scaffold technology in treating coronary bifurcation lesions: A report about long-term clinical results and review of available literature. Bratisl Lek Listy. 2019;120(8):545-551. doi: 10.4149/BLL_2019_088.
Barkholt TØ, Neghabat O, Holck EN, et al. Bioresorbable magnesium scaffold in the treatment of simple coronary bifurcation lesions: The BIFSORB pilot II study.Catheter Cardiovasc Interv. 2022;99(4):1075-1083. doi: 10.1002/ccd.30051.
Liang XY, Li Y, Zhang WJ, et al. Efficacy and safety of bioresorbable scaffolds in patients with coronary bifurcation lesions: A systematic review and meta-analysis. Cardiol J. 2022;29(4):563-573. doi: 10.5603/CJ.a2021.0040.
Bennett J, McCutcheon K, Vanhaverbeke M, et al. Complex Bifurcation Lesions: RAndomized Comparison of Modified-T Stenting vs Reconstruction With Self-Expanding Stent and Bioresorbable Scaffold: COBRA II.J Invasive Cardiol. 2021;33(4):E281-E293.
Jeger RV, Eccleshall S, Wan Ahmad WA,et al. Drug-Coated Balloons for Coronary Artery Disease Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv 2020;13(12):1391-1402. doi: 10.1016/j.jcin.2020.02.043.
Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med 2017;376:2319–28. doi: 10.1056/NEJMoa1614954
Speck U, Scheller B, Rutsch W, et al. Local drug delivery—the early Berlin experience: single drug administration versus sustained release. EuroIntervention 2011;7 supplK:K17–22.
Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969–76. doi: 10.1016/s0735-1097(00)00614-8
Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000;86:879–84.doi: 10.1161/01.res.86.8.879
Speck U, Scheller B, Abramjuk C, et al. Inhibition of restenosis in stented porcine coronary arteries: uptake of paclitaxel from angiographic contrast media. Invest Radiol 2004;39:182–6. doi: 10.1097/01.rli.0000116125.96544.64
Scheller B, Hehrlein C, Bocksch W, et al.Treatment of coronary in stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med2006;355:2113–24.doi: 10.1056/NEJMoa061254
Ali RM, Abdul Kader MASK, Wan Ahmad WA,et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. J Am Coll Cardiol Intv 2019;12:558–66. doi: 10.1016/j.jcin.2018.11.040
Mathey DG, Wendig I, Boxberger M, et al. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 2011;7 supplK:K61–5. doi: 10.4244/EIJV7SKA11
Worthley S, Hendriks R, Worthley M, et al. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations:12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med 2015;16:413–7.doi: 10.1016/j.carrev.2015.07.009
Bruch L, Zadura M, Waliszewski M, et al. Results from the International Drug Coated Balloon Registry for the Treatment of Bifurcations. Can a bifurcation be treated without stents? J Interv Cardiol 2016;29:348–56. doi: 10.4244/EIJV11I8A177
Corballis NH, Paddock S, Gunawardena, et al. Drug coated balloons for coronary artery bifurcation lesions: A systematic review and focused meta-analysis. PLoS One 2021;16(7):e0251986. doi: 10.1371/journal.pone.0251986.
Gao XF, Ge Z, Kan J, et al. Rationale and design for comparison of non-compliant balloon with drugcoating balloon angioplasty for side branch after provisional stenting for patients with true coronary bifurcation lesions: a prospective, multicentre and randomised DCB-BIF trial. BMJ Open2022;12(3):e052788. doi: 10.1136 / bmjopen-2021-052788.
Mishra S. Dedicated bifurcation stents – Mechanistic, hardware, and technical aspects. Indian heart journal.2016: 841-850. doi.org/10.1016/j.ihj.2015.07.054
Finet G, Gilard M, Perrenot B, et al. Fractal geometry of arterial coronary bifurcations: a quantitative coronary angiography and intravascular ultrasound analysis. EuroIntervention. 2008;3:490–498. doi: 10.4244/eijv3i4a87
Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation. 2006;114:1955–1961. doi: 10.1161/CIRCULATIONAHA.106.664920
Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113. doi: 10.1161/CIRCULATIONAHA.105.600155
Mohamed MO, Mamas MA, Nagaraja V, et al. Dedicated Bifurcation Stents forCoronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. J Invasive Cardiol. 2019;31(12):E344-E355.
Genereux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol. 2015;65:533-543.
Gil RJ, Bil J, Dzavik V, et al. Regular drug-eluting stent vs dedicated coronary bifurcation BiOSS Expert stent: multicenter open-label randomized controlled POLBOS I trial. Can J Cardiol. 2015;31:671-678. doi: 10.1016/j.cjca.2014.12.024.
Gil RJ, Bil J, Grundeken MJ, et al. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BIOSS LIM stent: the randomised, multicentre, open-label, controlled POLBOSS II trial. Eurointervention 2015; 11(7):20140419-05. doi: 10.4244/EIJY15M11_11
Dubois C, Bennett J, Dens J, et al. Complex coronary bifurcation lesions: randomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial. EuroIntervention. 2016;11:1457-1467.
Cervinka P, Bystron M, Spacek R, et al. Treatment of bifurcation lesions using dedicated bifurcation stents versus classic bare-metal stents. Randomized, controlled trial with 12-month angiographic follow up. J Invasive Cardiol. 2008;20:516-520.
Kiris A, Kiris G. Bifurkasyon Lezyonlarında Dedicated Stentler ve Gelecek. Sahin Kaplan (Ed.). Turkiye Klinikleri J Cardiol-Special Topics. 2017;10(2):114-20.
Ormiston J, Webster M, El-Jack S, et al. The AST Petal dedicated bifurcation stent: first-in-human experience. Catheter Cardiovasc Interv 2007; 70(3):335-40.doi: 10.1002/ccd.21206
Ormiston JA, Levefre T, Grube E, et al. First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent. Eurointervention 2010; 6(1):46-53.
Del Balanco BG, Marti G, Bellara N, et al. Clinical and procedural evaluation of the Nile Croco dedicated stent for bifurcations; a single centre experience with the first 151 consecutive non-selected patients. Eurointervention 2011; 7(2):216-24. doi: 10.4244/EIJV7I2A36
Verheye S, Grube EA, Ramcharitar S, et al. First-in-man (FIM) study of the Stentys bifurcation stent-30 days results. Eurointervention 2009; 4(5):566-71. doi: 10.4244/eijv4i5a96
Naber CK, Pyxaras SA, Nef H, et al. Final results of a self-apposing paclitaxel-eluting stent for the Percutaneous treatment of de novo lesions in native bifurcated coronary arteries study. Eurointervention 2016; 12(3):356-8. doi: 10.4244/EIJY15M06_02
Gil RJ, Vassiliev D, Michalek A, et al. First-in-man study of paclitaxel eluting stent BIOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results. KardiolPol 2012; 70(1):45-52.
Gil RJ, Vassilev D, Michalek A, et al. Dedicated paclitaxel-eluting bifurcation stent BIOSS (Bifurcation Optimisation Stent System): 12-month results from a prospective registry of consecutive all-corners population. Eurointervention 2012; 8(3):316-24. doi: 10.4244/EIJV8I3A50
Gil RJ, Vassilev D, Iniqo Garcia LA. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BIOSS LIM Registry. J IntervCardiol 2015; 28(1):51-60. doi: 10.1111/joic.12180
Mamas MA, Faoog V, Latib A, et al. Use of Sideguard (Cappella) stent in bifurcation lesions: a real-world experience. Eurointervention 2012; 7(10):1170-8. doi: 10.4244/EIJV7I10A188
Grundeken MJ, Asqedom S, Damman P, et al. Six-month an one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. Eurointervention 2013; 9(2):195-203. doi: 10.4244/EIJV9I2A34
MJ, Winter RJ, Wykrzykowska JJ. Safety and efficacy of the Tryton Side Branch Stent™ for the treatment of coronary bifurcation lesions: an update. Expert Review of Medical Devices, 14:7, 545-555, DOI: 10.1080/17434440.2017.133813.
Miyazawa A, Ako J, Hassan A et al. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system:intravascular ultrasound results of the AXXESS PLUS trial. doi: 10.1002/ccd.21269
Grube E, Buellesfeld L, Neumann F J. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol 2007 Jun 15;99(12):1691-7. doi: 10.1016/j.amjcard.2007.01.043.
Buysschaert I, Dubois CL, Dens J, et al. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention 2013;9(5):573-81. doi: 10.4244/EIJV9I5A93.
Verheye S, Buysscheart I, Grube E. Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system. EuroIntervention 2015 ;11(8):860-7. doi: 10.4244/EIJV11I8A176.
Beyar R, Davies JE, Cook C, et al. Robotics, imaging, and artificial intelligence in the catheterisation laboratory. EuroIntervention. 2021;17:537–549. doi: 10.4244/EIJ-D-21-00145.
Beyar R, Gruberg L, Deleanu D, et al. Remote- control percutaneous coronary interventions: concept, validation, and first-in-humans pilot clinical trial. J Am Coll Cardiol 2006;47: 296–300. doi: 10.1016/j.jacc.2005.09.024.
Granada JF, Delgado JA, Uribe MP, et al. First- in-human evaluation of a novel robotic-assisted coronary angioplasty system. J Am Coll Cardiol Intv 2011;4:460–5. doi: 10.1016/j.jcin.2010.12.007.
Weisz G, Metzger DC, Caputo RP, et al. Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (percutaneous robotically-enhanced coronary intervention) study. J Am Coll Cardiol 2013;61:1596–600. doi: 10.1016/j.jacc.2012.12.045.
Smilowitz NR, Weisz G. Robotic-assisted angioplasty: current status and future possibilities. Curr Cardiol Rep 2012;14:642–6. doi: 10.1007/s11886-012-0300-z.
Smilowitz NR, Moses JW, Sosa FA, et al. Robotic-enhanced PCI compared to the traditional manual approach. J Invasive Cardiol 2014;26: 318–21.
Mahmud E, Naghi J, Ang L, et al. Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions: Results of the CORA-PCI Study (Complex Robotically Assisted Percutaneous Coronary Intervention). JACC Cardiovasc Interv 2017;10(13):1320-1327. doi:10.1016/j.jcin.2017.03.050.
Khokhar A, Zelias A, Giannini F, et al. Hybrid step-by-step approach to perform a Robotic DK Crush PCI. EuroIntervention: image in cardiology 2022. https://www.pcronline.com/Cases-resources-images/Images-interventional-cardiology/EuroIntervention-images/Hybrid-step-by-step-approach-perform-Robotic-DK-Crush-PCI (12.07.2022 tarihinde ulaşılmıştır.)
